SSA
ENVB icon

Schonfeld Strategic Advisors’s Enveric Biosciences ENVB Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2
Closed -$62K – 2038
2021
Q1 		$62K Buy
+2
New +$69.9K ﹤0.01% 1710

Other funds holding ENVB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
EGM
Engineers Gate Manager New York $8B AUM 17.32% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Schonfeld Strategic Advisors's ENVB Position: Q2 2021 in Review

Schonfeld Strategic Advisors sold out of Enveric Biosciences (ENVB) in Q2 2021, closing a stake of 2 shares — an estimated $62K sold.

Schonfeld Strategic Advisors first reported a position in ENVB in Q1 2021 and held it in 1 quarter. The position peaked at $62K in Q1 2021. 14 funds tracked by Wall St. Rank hold ENVB as of Q2 2021.

  • Schonfeld Strategic Advisors reported no remaining Enveric Biosciences position as of Q2 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 2 Enveric Biosciences shares in Q2 2021, an estimated $62K.
  • Schonfeld Strategic Advisors first reported a position in Enveric Biosciences in Q1 2021 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Enveric Biosciences position peaked at $62K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.